{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:12:59Z","timestamp":1790741579430,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81870559"],"award-info":[{"award-number":["81870559"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170815"],"award-info":[{"award-number":["82170815"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81561128014"],"award-info":[{"award-number":["81561128014"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003347","name":"Fudan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010108","name":"Zhongshan Hospital Fudan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.molmet.2024.102026","type":"journal-article","created":{"date-parts":[[2024,9,17]],"date-time":"2024-09-17T22:11:27Z","timestamp":1726611087000},"page":"102026","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["IGFBP2 functions as an endogenous protector against hepatic steatosis via suppression of the EGFR-STAT3 pathway"],"prefix":"10.1016","volume":"89","author":[{"given":"Tianyu","family":"Zhai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingfeng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenling","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pu","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.molmet.2024.102026_bib1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.molmet.2024.102026_bib2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nrgastro.2011.273","article-title":"Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach","volume":"9","author":"Alisi","year":"2012","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.molmet.2024.102026_bib3","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.cld.2015.10.001","article-title":"Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world","volume":"20","author":"Sayiner","year":"2016","journal-title":"Clin Liver Dis"},{"issue":"24","key":"10.1016\/j.molmet.2024.102026_bib4","doi-asserted-by":"crossref","first-page":"5651","DOI":"10.1002\/cncr.24687","article-title":"Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link","volume":"115","author":"Siegel","year":"2009","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.molmet.2024.102026_bib5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrgastro.2017.32","article-title":"Lipid droplets and liver disease: from basic biology to clinical implications","volume":"14","author":"Gluchowski","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.molmet.2024.102026_bib6","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.molmet.2024.102026_bib7","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.cell.2009.05.036","article-title":"Identification of a physiologically relevant endogenous ligand for PPARalpha in liver","volume":"138","author":"Chakravarthy","year":"2009","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.molmet.2024.102026_bib8","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J\u00a0Clin Invest"},{"issue":"17\u201318","key":"10.1016\/j.molmet.2024.102026_bib9","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.drudis.2007.07.009","article-title":"Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD)","volume":"12","author":"Ahmed","year":"2007","journal-title":"Drug Discov Today"},{"issue":"2","key":"10.1016\/j.molmet.2024.102026_bib10","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/toxsci\/kfw213","article-title":"Dual role of epidermal growth factor receptor in liver injury and regeneration after acetaminophen overdose in mice","volume":"155","author":"Bhushan","year":"2017","journal-title":"Toxicol Sci"},{"issue":"2","key":"10.1016\/j.molmet.2024.102026_bib11","first-page":"190","article-title":"Gene expression profiling reveals key genes and pathways related to the development of non-alcoholic fatty liver disease","volume":"15","author":"Wang","year":"2016","journal-title":"Ann Hepatol"},{"issue":"5","key":"10.1016\/j.molmet.2024.102026_bib12","doi-asserted-by":"crossref","first-page":"G370","DOI":"10.1152\/ajpgi.00116.2013","article-title":"Epidermal growth factor receptor plays a role in the regulation of liver and plasma lipid levels in adult male mice","volume":"306","author":"Scheving","year":"2014","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"5","key":"10.1016\/j.molmet.2024.102026_bib13","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1002\/hep.30696","article-title":"Pharmacologic inhibition of epidermal growth factor receptor suppresses nonalcoholic fatty liver disease in a murine fast-food diet model","volume":"70","author":"Bhushan","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.molmet.2024.102026_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0210828","article-title":"Epidermal growth factor receptor inhibition attenuates non-alcoholic fatty liver disease in diet-induced obese mice","volume":"14","author":"Choung","year":"2019","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.molmet.2024.102026_bib15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.bbadis.2017.10.016","article-title":"Inhibition of EGFR attenuates fibrosis and stellate cell activation in diet-induced model of nonalcoholic fatty liver disease","volume":"1864","author":"Liang","year":"2018","journal-title":"Biochim Biophys Acta, Mol Basis Dis"},{"issue":"11","key":"10.1016\/j.molmet.2024.102026_bib16","doi-asserted-by":"crossref","first-page":"8815","DOI":"10.1002\/jcp.26795","article-title":"Key genes and functional coexpression modules involved in the pathogenesis of systemic lupus erythematosus","volume":"233","author":"Yan","year":"2018","journal-title":"J\u00a0Cell Physiol"},{"issue":"4","key":"10.1016\/j.molmet.2024.102026_bib17","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1093\/bioinformatics\/btr709","article-title":"Robust rank aggregation for gene list integration and meta-analysis","volume":"28","author":"Kolde","year":"2012","journal-title":"Bioinformatics"},{"issue":"9","key":"10.1016\/j.molmet.2024.102026_bib18","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.2337\/db11-1488","article-title":"Insulin-like growth factor axis and risk of type 2 diabetes in women","volume":"61","author":"Rajpathak","year":"2012","journal-title":"Diabetes"},{"issue":"9319","key":"10.1016\/j.molmet.2024.102026_bib19","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S0140-6736(02)08655-5","article-title":"Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study","volume":"359","author":"Sandhu","year":"2002","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.molmet.2024.102026_bib20","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1530\/EC-21-0353","article-title":"IGFBP-2 as a biomarker in NAFLD improves hepatic steatosis: an integrated bioinformatics and experimental study","volume":"10","author":"Chen","year":"2021","journal-title":"Endocr Connect"},{"key":"10.1016\/j.molmet.2024.102026_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2022.872518","article-title":"Identification of hub genes associated with non-alcoholic steatohepatitis using integrated bioinformatics analysis","volume":"13","author":"Meng","year":"2022","journal-title":"Front Genet"},{"issue":"2","key":"10.1016\/j.molmet.2024.102026_bib22","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.atherosclerosis.2014.09.022","article-title":"Circulating IGFBP-2 levels are incrementally linked to correlates of the metabolic syndrome and independently associated with VLDL triglycerides","volume":"237","author":"Carter","year":"2014","journal-title":"Atherosclerosis"},{"issue":"1","key":"10.1016\/j.molmet.2024.102026_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1677\/joe.0.1750003","article-title":"Comparative endocrinology of the insulin-like growth factor-binding protein","volume":"175","author":"Kelley","year":"2002","journal-title":"J\u00a0Endocrinol"},{"key":"10.1016\/j.molmet.2024.102026_bib24","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.canlet.2020.02.036","article-title":"IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma","volume":"477","author":"Li","year":"2020","journal-title":"Cancer Lett"},{"issue":"6","key":"10.1016\/j.molmet.2024.102026_bib25","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/onc.2015.131","article-title":"IGFBP2\u00a0potentiates nuclear EGFR-STAT3 signaling","volume":"35","author":"Chua","year":"2016","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.molmet.2024.102026_bib26","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/path.4829","article-title":"Animal models of non-alcoholic fatty liver disease:\u00a0current perspectives and recent advances","volume":"241","author":"Lau","year":"2017","journal-title":"J\u00a0Pathol"},{"issue":"1","key":"10.1016\/j.molmet.2024.102026_bib27","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-2275(20)32079-4","article-title":"Sterol regulatory element binding proteins (SREBP)-1a and SREBP-2 are linked to the MAP-kinase cascade","volume":"41","author":"Kotzka","year":"2000","journal-title":"J\u00a0Lipid Res"},{"issue":"9","key":"10.1016\/j.molmet.2024.102026_bib28","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/jcp.48.9.876","article-title":"A\u00a0\"quickscore\" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas","volume":"48","author":"Detre","year":"1995","journal-title":"J\u00a0Clin Pathol"},{"issue":"8","key":"10.1016\/j.molmet.2024.102026_bib29","article-title":"Circulating IGFBP-2 levels are inversely associated with the incidence of nonalcoholic fatty liver disease: a cohort study","volume":"48","author":"Yang","year":"2020","journal-title":"J\u00a0Int Med Res"},{"issue":"1","key":"10.1016\/j.molmet.2024.102026_bib30","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1023\/A:1022518321634","article-title":"Lifestyle determinants of serum insulin-like growth-factor-I (IGF-I), C-peptide and hormone binding protein levels in British women","volume":"14","author":"Allen","year":"2003","journal-title":"Cancer Causes Control"},{"issue":"7","key":"10.1016\/j.molmet.2024.102026_bib31","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-2006-924320","article-title":"Insulin-like growth factor binding protein-2 (IGFBP-2) is a marker\u00a0for\u00a0the\u00a0metabolic syndrome","volume":"114","author":"Heald","year":"2006","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"12","key":"10.1016\/j.molmet.2024.102026_bib32","first-page":"2588","article-title":"Early hypermethylation of hepatic Igfbp2 results in its reduced expression preceding fatty liver in mice","volume":"25","author":"Kammel","year":"2016","journal-title":"Hum Mol Genet"},{"issue":"11","key":"10.1016\/j.molmet.2024.102026_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21114144","article-title":"Physiological disturbance in fatty liver energy metabolism converges on IGFBP2 abundance and regulation in mice and men","volume":"21","author":"Fahlbusch","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.molmet.2024.102026_bib34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cmet.2009.11.007","article-title":"Antidiabetic effects of IGFBP2, a leptin-regulated gene","volume":"11","author":"Hedbacker","year":"2010","journal-title":"Cell Metabol"},{"issue":"9","key":"10.1016\/j.molmet.2024.102026_bib35","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1210\/mend.14.9.0517","article-title":"Selective alterations in organ sizes in mice with a targeted disruption of the insulin-like growth factor binding protein-2 gene","volume":"14","author":"Wood","year":"2000","journal-title":"Mol Endocrinol"},{"issue":"2\u20134","key":"10.1016\/j.molmet.2024.102026_bib36","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/0955-2235(95)00029-1","article-title":"Genetic ablation of IGFBP-2 suggests functional redundancy in the IGFBP family","volume":"6","author":"Pintar","year":"1995","journal-title":"Prog Growth Factor Res"},{"issue":"2","key":"10.1016\/j.molmet.2024.102026_bib37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2337\/db06-0436","article-title":"IGF-binding protein-2 protects against the development of obesity and insulin resistance","volume":"56","author":"Wheatcroft","year":"2007","journal-title":"Diabetes"},{"issue":"12","key":"10.1016\/j.molmet.2024.102026_bib38","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1210\/endo.140.12.7169","article-title":"Overexpression of insulin-like growth factor-binding protein-2 in transgenic mice reduces postnatal body weight gain","volume":"140","author":"Hoeflich","year":"1999","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.molmet.2024.102026_bib39","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1210\/er.2001-0033","article-title":"Cellular actions of the insulin-like growth factor binding proteins","volume":"23","author":"Firth","year":"2002","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.molmet.2024.102026_bib40","doi-asserted-by":"crossref","first-page":"E409","DOI":"10.1152\/ajpendo.00168.2015","article-title":"The RGD sequence present in IGFBP-2 is required for reduced glucose clearance after oral glucose administration in female transgenic mice","volume":"309","author":"Reyer","year":"2015","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.molmet.2024.102026_bib41","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/en.2013-1236","article-title":"The heparin-binding domains of IGFBP-2 mediate its inhibitory effect on preadipocyte differentiation and fat development in male mice","volume":"154","author":"Xi","year":"2013","journal-title":"Endocrinology"},{"issue":"9","key":"10.1016\/j.molmet.2024.102026_bib42","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1073\/pnas.1120375109","article-title":"Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-kappaB network","volume":"109","author":"Holmes","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"13","key":"10.1016\/j.molmet.2024.102026_bib43","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1073\/pnas.0609139104","article-title":"Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K\/Akt pathway activation in glioblastoma and prostate cancer","volume":"104","author":"Mehrian-Shai","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"10.1016\/j.molmet.2024.102026_bib44","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/bjc.2014.435","article-title":"Exogenous IGFBP-2 promotes proliferation, invasion, and chemoresistance to temozolomide in glioma cells via the integrin beta1-ERK pathway","volume":"111","author":"Han","year":"2014","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.molmet.2024.102026_bib45","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1210\/en.2011-1121","article-title":"IGFBP-2 enhances VEGF gene promoter activity and consequent promotion of angiogenesis by neuroblastoma cells","volume":"152","author":"Azar","year":"2011","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.molmet.2024.102026_bib46","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1016\/j.cell.2018.09.053","article-title":"Obesity drives STAT-1-dependent NASH and STAT-3-dependent HCC","volume":"175","author":"Grohmann","year":"2018","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.molmet.2024.102026_bib47","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/nrm3048","article-title":"Feedback regulation of EGFR signalling: decision making by early and delayed loops","volume":"12","author":"Avraham","year":"2011","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"24","key":"10.1016\/j.molmet.2024.102026_bib48","doi-asserted-by":"crossref","first-page":"13704","DOI":"10.1073\/pnas.93.24.13704","article-title":"In\u00a0vitro activation of Stat3 by epidermal growth factor receptor kinase","volume":"93","author":"Park","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"34","key":"10.1016\/j.molmet.2024.102026_bib49","doi-asserted-by":"crossref","first-page":"30716","DOI":"10.1074\/jbc.M202823200","article-title":"Identification of both positive and negative domains within the epidermal growth factor receptor COOH-terminal region for signal transducer and activator of transcription (STAT) activation","volume":"277","author":"Xia","year":"2002","journal-title":"J\u00a0Biol Chem"},{"issue":"4","key":"10.1016\/j.molmet.2024.102026_bib50","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/hep.20400","article-title":"Interleukin 6 alleviates hepatic steatosis and ischemia\/reperfusion injury in mice with fatty liver disease","volume":"40","author":"Hong","year":"2004","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.molmet.2024.102026_bib51","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jhep.2010.03.004","article-title":"Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22","volume":"53","author":"Yang","year":"2010","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.molmet.2024.102026_bib52","first-page":"E200","article-title":"Role of hepatic STAT3 in the regulation of lipid metabolism","volume":"54","author":"Kinoshita","year":"2008","journal-title":"Kobe J Med Sci"},{"issue":"20","key":"10.1016\/j.molmet.2024.102026_bib53","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.7150\/thno.27425","article-title":"miR-125a-5p ameliorates hepatic glycolipid metabolism disorder in type 2 diabetes mellitus through targeting of STAT3","volume":"8","author":"Xu","year":"2018","journal-title":"Theranostics"},{"issue":"9","key":"10.1016\/j.molmet.2024.102026_bib54","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1001\/jama.2020.0812","article-title":"New insight on preventing EGFR inhibitor-induced adverse effects","volume":"323","author":"Hampton","year":"2020","journal-title":"JAMA"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877824001571?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877824001571?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T06:12:12Z","timestamp":1729491132000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877824001571"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":54,"alternative-id":["S2212877824001571"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2024.102026","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IGFBP2 functions as an endogenous protector against hepatic steatosis via suppression of the EGFR-STAT3 pathway","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2024.102026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"102026"}}